NeuroVive Pharmaceutical AB (publ): Report from AGM
NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 28 April 2016. A summary of the resolutions follows. All resolutions were passed with the required majority.
Press releases
NeuroVive insiders and employees intend to subscribe for a minimum of 5.4 million SEK
NeuroVive Pharmaceutical AB (publ) announces that board members, other insiders and employees intend to subscribe for a minimum of 129 000 units, equivalent to at least SEK 5.4 million, in the company ...
NeuroVive starts preclinical TBI program in collaboration with PENN
NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, announces the start of the first study in the preclinical program in traumatic brain injury (TBI) which is being done in col ...
NeuroVive: large shareholder to participate in the rights issue
NeuroVive Pharmaceutical AB (publ) announces that Baulos Capital Belgium SA, one of the largest shareholders, intends to participate in the upcoming rights issue.
NeuroVive Pharmaceutical AB (publ): report from EGM
Today, 31 March 2016, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company"). A summary of the resolutions follows. All resolutions were passed ...
Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)
The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 4 p.m. on Thursday, 28 April 2016 at Medicon V ...
NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation
NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, announces that the independent safety committee has once again endorsed the continuation of the ongoing Phase II CiPRICS (Ci ...
Notice of extraordinary general meeting in NeuroVive Pharmaceutical AB (publ)
The shareholders in NeuroVive Pharmaceutical AB (publ) reg. no. 556595-6538 (the "Company") are hereby convened to the extraordinary general meeting, held at 10.00 a.m. on Thursday, 31 March 2016 at ...
NeuroVive enters strategic collaboration with University of Pennsylvania
Lund, Sweden, 12 January 2016 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has entered into a research partnership with University of Pennsylvania to enh ...
NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study
Lund, Sweden, 19 November 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed the continuation of the on-going P ...
NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus
Lund, Sweden, 28 October 2015- NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that they will seek to find a suitable path forward to continue the development of the ...
NeuroVive Strengthens Clinical Development Team With Appointment of Dr. Magnus Hansson as Chief Medical Officer
Lund, Sweden, 23 October 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that Dr. Magnus Hansson will be appointed as Chief Medical Officer, effective as of 1 ...